Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

257.10GBp
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
257.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,109,884
52-wk High
504.60
52-wk Low
238.00

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: 1.72
Market Cap(Mil.): £1,921.72
Shares Outstanding(Mil.): 728.31
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 43.11 30.48 32.69
EPS (TTM): 0.06 -- --
ROI: 14.27 13.04 12.72
ROE: -- 14.99 14.85

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Sep 12 2018

UPDATE 1-Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Sep 12 2018

Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Sep 12 2018

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Aug 08 2018

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

Aug 8 The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Aug 08 2018

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Jul 31 2018

UPDATE 1-Indivior: U.S. court rules against generic rival's appeal

July 31 Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Jul 31 2018

Indivior says U.S. court rules against generic rival's appeal

July 31 Indivior Plc said on Tuesday a U.S. court ruled against Dr. Reddy's Laboratories appeal for lifting the preliminary injunction on the rival's copycat opioid addiction treatment in the United States.

Jul 31 2018

U.S. court expedites Indivior rival's appeal to re-launch generic drug

Indivior said on Monday a U.S. Court expedited a generic rival's appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker's blockbuster opioid addiction treatment.

Jul 30 2018

Indivior says generic's appeal gets granted-in-part motion on preliminary injunction

July 30 Indivior Plc on Monday said a U.S. Court granted-in-part a motion to expedite a rival's appeal of a preliminary injunction that blocked the sale of copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

Jul 30 2018

Earnings vs. Estimates